Yubo International Biotech Limited
Σύμβολο: YBGJ
PNK
0.325
USDΤιμή αγοράς σήμερα
-175.4014
Λόγος P/E
-1.8389
Δείκτης PEG
38.94M
MRK Cap
- 0.00%
DIV Απόδοση
Yubo International Biotech Limited (YBGJ) Οικονομικές καταστάσεις
Ισολογισμός
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 0 | 0 | 1.4 | ||||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 0.3 | 0.6 | 0.4 | ||||||||||||||||||||
balance-sheet.row.inventory | 0 | 0.3 | 0.2 | 0.1 | ||||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 0.4 | 0.3 | 0 | ||||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 0.8 | 1.1 | 1.9 | ||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1.4 | 3.3 | 0.4 | ||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 0.1 | 0 | 0.1 | ||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0.1 | 0 | 0.1 | ||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0.1 | 0.2 | 0.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 1.6 | 3.5 | 0.5 | ||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-assets | 0 | 2.3 | 4.6 | 2.4 | ||||||||||||||||||||
balance-sheet.row.account-payables | 0 | 0.5 | 0.3 | 0.1 | ||||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 0.4 | 0.8 | 0.3 | ||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0.4 | 1.9 | 0 | ||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 1.1 | 1.3 | 0.1 | ||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 0.4 | 1.9 | 0 | ||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0.8 | 2.7 | 0.3 | ||||||||||||||||||||
balance-sheet.row.total-liab | 0 | 2.9 | 4.7 | 1.3 | ||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.common-stock | 0 | 0.1 | 0.1 | 0.1 | ||||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -3.7 | -2.5 | -0.9 | ||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0.1 | 0.1 | 0 | ||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 2.9 | 2.1 | 2 | ||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | -0.6 | -0.1 | 1.2 | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 2.3 | 4.6 | 2.4 | ||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-equity | 0 | - | - | - | ||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
balance-sheet.row.total-debt | 0 | 0.8 | 2.7 | 0.3 | ||||||||||||||||||||
balance-sheet.row.net-debt | 0 | 0.8 | 2.7 | -1.1 |
Κατάσταση ταμειακών ροών
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -1.2 | -1.5 | -0.7 | ||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 1.2 | 0.5 | 0.8 | ||||||||||||||||||||
cash-flows.row.account-receivables | 0 | 0.1 | -0.2 | 0 | ||||||||||||||||||||
cash-flows.row.inventory | 0 | -0.2 | -0.1 | -0.1 | ||||||||||||||||||||
cash-flows.row.account-payables | 0 | 0.3 | 0.2 | 0.1 | ||||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 1 | 0.6 | 0.8 | ||||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.6 | -0.1 | ||||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | -0.6 | -0.1 | ||||||||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0.8 | ||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0.1 | 0.6 | ||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 0.1 | 1.4 | ||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0.1 | 0 | ||||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | -1.4 | 1.4 | ||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 0 | 0 | 1.4 | ||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 0 | 1.4 | 0 | ||||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 0.1 | -1 | 0.1 | ||||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.6 | -0.1 | ||||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | -1.6 | 0 |
Σειρά κατάστασης λογαριασμού αποτελεσμάτων
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0.1 | 1.2 | 1.4 | ||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0.1 | 0.4 | 0.1 | ||||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 0.1 | 0.8 | 1.2 | ||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0.2 | 0.9 | 0.8 | ||||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 1.3 | 2.4 | 2 | ||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1.3 | 2.8 | 2.1 | ||||||||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 427 | -0.1 | ||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0.2 | 0.9 | 0.8 | ||||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | 427 | -0.1 | ||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||||||
income-statement-row.row.operating-income | 0 | -1.2 | -1.5 | -0.7 | ||||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -1.2 | -1.5 | -0.7 | ||||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 0 | 0 | ||||||||||||||||||||
income-statement-row.row.net-income | 0 | -1.2 | -1.5 | -0.7 |
Συχνές ερωτήσεις
Ποιο είναι το Yubo International Biotech Limited (YBGJ) το σύνολο του ενεργητικού?
Yubo International Biotech Limited (YBGJ) το συνολικό ενεργητικό είναι 2348551.000.
Ποια είναι τα ετήσια έσοδα της επιχείρησης?
Τα ετήσια έσοδα είναι N/A.
Ποιο είναι το περιθώριο κέρδους της επιχείρησης?
Το περιθώριο κέρδους της επιχείρησης είναι 0.390.
Ποια είναι η ελεύθερη ταμειακή ροή της επιχείρησης?
Η ελεύθερη ταμειακή ροή είναι -0.002.
Ποιο είναι το καθαρό περιθώριο κέρδους της επιχείρησης?
Το καθαρό περιθώριο κέρδους είναι -2.586.
Ποια είναι τα συνολικά έσοδα της επιχείρησης?
Τα συνολικά έσοδα είναι -2.620.
Ποια είναι η Yubo International Biotech Limited (YBGJ) καθαρό κέρδος (καθαρό εισόδημα)?
Το καθαρό κέρδος (καθαρό εισόδημα) είναι -1204765.000.
Ποιο είναι το συνολικό χρέος της επιχείρησης?
Το συνολικό χρέος είναι 790499.000.
Ποιος είναι ο αριθμός των λειτουργικών εξόδων?
Τα λειτουργικά έξοδα είναι 1257875.000.
Ποιος είναι ο αριθμός των ταμειακών διαθεσίμων της εταιρείας?
Τα ταμειακά διαθέσιμα της επιχείρησης είναι 0.000.